24/7 Market News Snapshot 08 May, 2025 – Delcath Systems Inc (NASDAQ:DCTH)

May 8, 2025

DENVER, Colo., 08 May, 2025 (www.247marketnews.com) – (NASDAQ:DCTH) are discussed in this article.
Delcath Systems Inc. (DCTH) has achieved significant milestones, as evidenced by its recent stock performance and robust financial results for the first quarter of 2025. Opening at $14.00, the stock surged to $14.465, representing an impressive increase of 24.59% from a previous close of $11.61. This strong market activity, further underlined by a trading volume of 775.64K shares, underscores an increasing investor confidence in Delcath’s innovative healthcare solutions.

In terms of financial performance, Delcath reported total revenues of $19.8 million for the quarter ending March 31, 2025, a substantial rise from $3.1 million during the same quarter in 2024. The surge in revenue was primarily driven by HEPZATO KIT™, which generated $18.0 million compared to $2.0 million in the prior year. Furthermore, the company celebrated its first quarter of net income, totaling $1.1 million, a significant turnaround from a net loss of $11.1 million in the same period last year. The adjusted EBITDA of $7.6 million also marked a considerable improvement from a loss of $7.3 million in Q1 2024, with gross margins increasing to 86% from 71%.

In addition to its financial advancements, Delcath expanded its treatment network by activating three new U.S. centers along with four additional centers in early 2025. This expansion brings Delcath’s total to 19 active locations. The company’s commitment to innovative research is evident with the FDA clearance of an IND application for a Phase 2 clinical trial assessing HEPZATO™ for liver-dominant metastatic breast cancer.

CEO Gerard Michel emphasized the significance of these achievements, stating that the growth in revenue and the expansion of treatment centers reflect strong market validation and innovative strategies directed at addressing the critical needs of liver cancer patients. Delcath Systems remains steadfast in its mission to advance oncology solutions and drive continued industry innovation.

Related news for (DCTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.